纹状体注射不同剂量6-OHDA制备帕金森病小鼠模型的评价

doi:10.3969/j.issn.1006-7795.2015.02.017

摘要/Abstract

摘要： 目的纹状体内注射6-OHDA可用于制备帕金森病(Parkinson's disease,PD)模型,其在小鼠模型上的行为学、形态学及多巴胺水平的变化需要进行系统评价。方法在小鼠右侧纹状体背外侧部立体定位分别注入4、6、8及10 μg的6羟基多巴胺(6-hydroxydopamine,6-OHDA),动态观察各剂量组小鼠的基本生理状况。旋转行为和转棒行为可评价PD小鼠的运动症状; 酪氨酸羟化酶(tyrosine hydroxylase,TH)免疫组化染色可反映黑质-纹状体内多巴胺能系统的功能改变;高效液相色谱法能检测多巴胺(dopamine,DA)及其代谢产物的含量并分析DA代谢率。结果除了10 μg 6-OHDA组的小鼠体质量呈一过性下降,其他剂量对小鼠体质量无显著影响。在6-OHDA注射一周后,各组小鼠均出现了持续性的异常旋转行为增加。此外,高剂量组(8 μg及10 μg)小鼠的转棒时间较低剂量组(4 μg及6 μg)小鼠明显缩短。TH组织化学染色显示,低剂量组小鼠损伤侧丢失了约60%的多巴胺神经元及40%的多巴胺神经纤维;而高剂量组小鼠则有超过80%的多巴胺神经元丢失和70%的多巴胺神经纤维减少。各组小鼠损伤侧纹状体内的DA水平及其代谢产物含量也显著降低,与6-OHDA注射量具有剂量依赖性;而DA代谢率却出现了代偿性增加改变。结论纹状体内注射不同剂量6-OHDA均能引起一定程度的PD病理表型,其损伤程度与6-OHDA剂量相关,为研究PD不同病理阶段及其干预策略提供了新的模型。

关键词: 6-羟基多巴胺, 纹状体, 帕金森病, 小鼠模型

Abstract: Objective To establish different 6-hydroxydopamine(6-OHDA) lesioned mice model, we evaluated the behavioral, neurochemical and histological effect of different dosage injection of 6-OHDA on motor dysfunction and dopamine denervation. Methods Different doses of 6-OHDA(4 μg, 6 μg, 8 μg, 10 μg) were injected into the right dorsal striatum under the facilitation of stereotactic equipment. The body weight after 6-OHDA injection was observed. Apomorphine-induced rotation and rota-rod test were used to estimate motor impairment. Tyrosine hydroxylase(TH) immunostaining was performed to determine the dopaminergic cell loss. Dopamine(DA) content was determined by HPLC. Results 10 μg 6-OHDA injection induced a temporary weight loss, while as other dose of 6-OHDA had no obvious effect on the body weight of mice. At the 1st week after the injection of 6-OHDA, the positive apomorphine induced rotation was observed and this rotational performance was stable for at least 5 weeks. The mice of 8 μg and 10 μg 6-OHDA injection decreased the latency time on the rota-rod. TH-immunolabeling indicated that the 4 μg and 6 μg 6-OHDA injections reduced the number of 60% DA neurons and 40% fibers, as well as 8 μg and 10 μg 6-OHDA injections reduced the number of 80% DA neurons and 70% fibers. Besides, 6-OHDA injection leads to the significant decrease of striatal DA and its metabolites. The decreased of DA content showed a positive correlation with the injection dosage of 6-OHDA, and a negative correlation with dopamine availability(DOPAC+HVA/DA). Conclusion 4 μg and 6 μg 6-OHDA injection induced partial lesions of the nigrostriatal DA system to mimic the early phases of Parkinson's disease(PD). 8 μg and 10 μg 6-OHDA injection induced completely lesions of the nigrostriatal DA system to mimic the late phases of PD.

Key words: 6-hydroxydopamine, striatum, Parkinson's disease, mice model

中图分类号:

于燕, 王可, 贾军, 王晓民. 纹状体注射不同剂量6-OHDA制备帕金森病小鼠模型的评价[J]. 首都医科大学学报, 2015, 36(2): 255-261.

Yu Yan, Wang Ke, Jia Jun, Wang Xiaomin. Establishment and evaluation of the striatal 6-OHDA lesioned mice model of Parkinson's disease[J]. Journal of Capital Medical University, 2015, 36(2): 255-261.

参考文献

[1] Blandini F, Armentero M T. Animal models of Parkinson's disease[J]. FEBS J, 2012,279(7):1156-1166.
[2] Dowd E, Dunnett S B. Comparison of 6-hydroxydopamine induced medial forebrain bundle and nigrostriatal terminal lesions in a lateralised nose-poking task in rats[J]. Behav. Brain Res, 2005,159(1):153-161.
[3] Iancu R, Mohapel P, Brundin P, et al. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice[J]. Behav Brain Res, 2005,162(1):1-10.
[4] Lundblad M, Picconi B, Lindgren H, et al. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice:relation to motor and cellular parameters of nigrostriatalfunction[J]. Neurobiol Dis, 2004,16(1):110-123.
[5] Grealish S, Mattsson B, Draxler P, et al. Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease[J]. Eur J Neurosci, 2010,31(12):2266-2278.
[6] Boix J, Padel T, Paul G. A partial lesion model of Parkinson's disease in mice-Characterization of a 6-OHDA-induced medial forebrain bundle lesion[J]. Behav Brain Res, 2015,284:196-206.
[7] BranchiI, D'Andrea I, Armida M, et al. Striatal 6-OHDA lesion in mice:Investigating early neurochemical changes underlying Parkinson' s disease[J]. Behav Brain Res, 2010,208(1):137-143.
[8] Kim S N, Doo A R, Park J Y, et al. Combined treatment with acupuncture reduces effective dose and alleviates adverse effect of L-dopa by normalizing Parkinson's disease-induced neurochemical imbalance[J]. Brain Res, 2014,1544:33-44.
[9] Ichitani Y, Okamura H, Nakahara D, et al. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system:evidence for cell death in the substantia nigra[J]. Exp Neurol, 1994,130(2):269-278.
[10] Bové J, Perier C. Neurotoxin-based models of Parkinson's disease[J]. Neuroscience, 2012,211:51-76.
[11] Lindgren H S, Lelos M J, Dunnett S B. Do α-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model?[J]. Exp Neurol, 2012,237(1):36-42.
[12] Alvarez-Fischer D, Henze C, Strenzke C, et al. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice[J]. Exp Neurol, 2008,210(1):182-193.
[13] Heuer A, Smith G A, Lelos M J, et al. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I:motor impairments identify extent of dopamine depletion at three different lesion sites[J]. Behav Brain Res, 2012,228(1):30-43.
[14] Rozas G, Labandeira García J L. Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test[J]. Brain Res, 1997,749(2):188-199.
[15] Von Wrangel C, Schwabe K, John N, et al. The rotenone-induced rat model of Parkinson's disease:behavioral and electrophysiological findings[J]. Behav Brain Res, 2015,279:52-61.
[16] Blandini F, Levandis G, Bazzini E et al. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat:new clues from an old model[J]. Eur J Neurosci, 2007,25(2):397-405.
[17] Yuan H, Sarre S, Ebinger G, et al. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease[J]. J Neurosci Methods, 2005,144(1):35-45.
[18] 张如意,张丽,吴燕川,等.二苯乙烯苷对PD模型小鼠干预作用的观察及机制初探[J].首都医科大学学报,2014,35(6):735-740.
[19] Qi Z, Miller G W, Voit E O. Rotenone and paraquat perturb dopamine metabolism:A computational analysis of pesticide toxicity[J]. Toxicology, 2014,315:92-101.
[20] Goes A T, Souza L C, Filho C B, et al. Neuroprotective effects of swimming training in a mouse model of Parkinson's disease induced by 6-hydroxydopamine[J]. Neuroscience, 2014,256:61-71.
[21] Kim S N, Doo A R, Park J Y, et al. Acupuncture enhances the synaptic dopamine availability to improve motor function in a mouse model of Parkinson's disease[J]. PLoS One, 2011,6(11):e27566.